http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101328660-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-0077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101328660-B1 |
| titleOfInvention | Polycaprolactone polymer carrier carrying anti-cancer drug sorafenib and drug controlled release stent using same |
| abstract | The present invention is a polycaprolactone loaded with an anticancer agent sorafenib (Sorafenib) to provide a new treatment using sorafenib by modifying the oral administration anti-cancer drug sorafenib in a polymer carrier and transforming it into a drug release control type and applying it to a stent. It relates to a polymer carrier and drug controlled release stent using the same. According to an aspect of the present invention for achieving the above object, sorafenib (Sorafenib) is made by supporting polycaprolactone (Poly (ε-caprolactone), PCL), the polycaprolactone is biodegradable in human tissue According to the present invention, there is provided a drug-controlled release therapeutic polymer carrier for releasing sound penib, or a stent to which the polymer carrier is attached to an outer surface thereof. In the present invention, by transforming sorafenib used as an oral anticancer agent into a drug delivery form, forming a new field of application of sorafenib to provide a new method of patient treatment, and also by using a sorafenib-supported stent. There is another effect of preventing the damage to the human body by the mode of administration, suppressing drug resistance as well as lessening the side effects of the treatment of local biliary tract cancer, thereby reducing the patient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160136802-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160134238-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170037780-A |
| priorityDate | 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.